DeepMed Research

Acetylcysteine

Generic Name: Acetylcysteine

Brand Names: Acetadote

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉NO_₃S

CAS Number: 616-91-1

Unique Ingredient Identifier: WYQ7N0BPYC

Background: Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication: Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions: Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis

Associated Therapies: Airway secretion clearance therapy

Clinical Trials

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

Early Phase 1

Withdrawn

Conditions: COVID-19

Interventions: Drug: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)

First Posted Date: 2022-05-12

Last Posted Date: 2024-11-05

Lead Sponsor: University of California, Irvine

Target Recruit Count: 50

Registration Number: NCT05371288

Locations: 🇺🇸
University of California Irvine Medical Center, Orange, California, United States

Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)

Not Applicable

Conditions: Alcoholic Hepatitis

Interventions: Drug: N-acetylcysteine

First Posted Date: 2022-03-24

Last Posted Date: 2022-03-24

Lead Sponsor: Bioaraba Health Research Institute

Target Recruit Count: 390

Registration Number: NCT05294744

Locations: 🇪🇸
Ana Belén Fernández Laso, Vitoria-Gasteiz, Álava, Spain

Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease

Phase 1

Conditions: COVID-19 Pneumonia
COVID-19
Ventilator Associated Pneumonia
COVID-19 Acute Respiratory Distress Syndrome

Interventions: Drug: Bromelains
Drug: Acetylcysteine

First Posted Date: 2022-02-28

Last Posted Date: 2022-02-28

Lead Sponsor: Mucpharm Pty Ltd

Target Recruit Count: 30

Registration Number: NCT05258682

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Phase 1

Recruiting

Conditions: Mitochondrial Disease

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2022-02-15

Last Posted Date: 2023-03-22

Lead Sponsor: Michio Hirano, MD

Target Recruit Count: 18

Registration Number: NCT05241262

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms

Phase 1

Recruiting

Conditions: Polycythemia Vera
Myelofibrosis
Myeloproliferative Neoplasm
Essential Thrombocythemia
MPN

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2021-11-17

Last Posted Date: 2025-02-10

Lead Sponsor: University of California, Irvine

Target Recruit Count: 27

Registration Number: NCT05123365

Locations: 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: N-Acetylcysteine

First Posted Date: 2021-10-18

Last Posted Date: 2025-05-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT05081479

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

NAC for Attenuation of COVID-19 Symptomatology

Phase 2

Not yet recruiting

Conditions: Covid19
COVID-19 Lower Respiratory Infection
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Oxidative Stress
COVID-19 Pneumonia
SARS-CoV-2 Acute Respiratory Disease
COVID-19 Respiratory Infection
SARS-CoV2 Infection

Interventions: Other: Placebo
Drug: N-acetylcysteine

First Posted Date: 2021-10-12

Last Posted Date: 2023-08-07

Lead Sponsor: Cambridge Health Alliance

Target Recruit Count: 200

Registration Number: NCT05074121

Locations: 🇺🇸
Cambridge Health Alliance, Everett, Massachusetts, United States

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Phase 3

Not yet recruiting

Conditions: Common Cold

Interventions: Drug: Acetylcysteine
Drug: Paracetamol
Drug: Phenylephrine

First Posted Date: 2021-10-07

Last Posted Date: 2024-08-07

Lead Sponsor: Sandoz

Target Recruit Count: 1002

Registration Number: NCT05070650

Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

Phase 1

Conditions: Pseudomyxoma Peritonei

Interventions: Drug: Bromelin
Drug: N-Acetylcysteine

First Posted Date: 2021-07-29

Last Posted Date: 2022-06-02

Lead Sponsor: Maimónides Biomedical Research Institute of Córdoba

Target Recruit Count: 10

Registration Number: NCT04982146

Locations: 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Spain

A Study of NAC for AUD

Phase 2

Withdrawn

Conditions: Alcohol Use Disorder

Interventions: Drug: N-acetylcysteine
Drug: Placebo

First Posted Date: 2021-07-16

Last Posted Date: 2023-07-21

Lead Sponsor: Uniformed Services University of the Health Sciences

Registration Number: NCT04964843

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy